COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,637 Articles (22,913 medRxiv, 8,724 bioRxiv)

Most recent first Previous |  Page 1633: Articles 16321-16330  | Next

Strategies for COVID-19 vaccination under a shortage scenario: a geo-stochastic modelling approach.
Barreiro, N. L., Ventura, C. I., Govezensky, T., Nunez, M., Bolcatto, P. G., Barrio, R. A.
10.1101/2021.04.19.21255745 — Posted: 2021-04-22
Evolution of case fatality rates in the second wave of coronavirus in England: effects of false positives, a Variant of Concern and vaccination.
Ackland, J. A., Ackland, G. J., Wallace, D. J.
10.1101/2021.04.14.21255385 — Posted: 2021-04-22
Preexisting and new-onset diabetes in patients with COVID-19 pneumonia
Laurenzi, A., Caretto, A., Molinari, C., Bazzigaluppi, E., Brigatti, C., Marzinotto, I., Mercalli, A., Melzi, R., Nano, R., Tresoldi, C., Landoni, G., Ciceri, F., Lampasona, V., Scavini, M., Piemonti, L.
10.1101/2021.04.17.21255548 — Posted: 2021-04-22
Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland
McDonald, L., Wise, H., Muecksch, F., Poston, D., Mavin, S., Templeton, K., Furrie, E., Richardson, C., McGuire, J., Jarvis, L., Malloy, K., McAuley, A., Palmateer, N., Dickson, E., Hatziioannou, T., Bieniasz, P., Jenks, S.
10.1101/2021.04.20.21255596 — Posted: 2021-04-22
Single dose of BNT162b2 mRNA vaccine against SARS-CoV2 induces neutralizing antibody and polyfunctional T-cell responses in patients with CML
Harrington, P., Doores, K., Radia, D., O'Reilly, A., Lam, H. P. J., Seow, J., Graham, C., Lechmere, T., McLornan, D., Dillon, R., Shanmugharaj, Y., Espehana, A., Woodley, C., Saunders, J., Curto-Garcia, N., O'Sullivan, J., Kordasti, S., Malim, M. H., Harrison, C., de Lavallade, H.
10.1101/2021.04.15.21255482 — Posted: 2021-04-22
ReCOVer study: A Cross-sectional Observational Study to Identify the Rehabilitation Need in Post-discharge COVID-19 Survivors
Swarnakar, R., Yadav, S. L., V, S., Soni, K. D., Aggrawal, R., Trikha, A.
10.1101/2021.04.19.21255750 — Posted: 2021-04-22
B and T cell immune responses elicited by the BNT162b2 (Pfizer BioNTech) COVID-19 vaccine in nursing home residents
Torres, I., Albert, E., Gimenez, E., Alcaraz, M. J., Botija, P., Amat, P., Remigia, M. J., Beltran, M. J., Rodado, C., Huntley, D., Olea, B., Navarro, D.
10.1101/2021.04.19.21255723 — Posted: 2021-04-22
Prolonged activation of nasal immune cell populations and development of tissue-resident SARS-CoV-2 specific CD8 T cell responses following COVID-19
Roukens, A. H. E., Konig, M., Dalebout, T., Tak, T., Azimi, S., Kruize, Y., Pothast, C. R., Hagedoorn, R. S., Arbous, S. M., Zhang, J. L. H., Verheij, M., Prins, C., Does, A. M., Hiemstra, P. S., Vries, J. J. C., Janse, J. J., Roestenberg, M., Myeni, S. K., Kikkert, M., Heemskerk, M. H. M., Yazdanbakhsh, M., Smits, H. H., Jochems, S. P., BEAT-COVID group, , COVID-19 LUMC group
10.1101/2021.04.19.21255727 — Posted: 2021-04-22
SARS-CoV-2 natural antibody response persists up to 12 months in a nationwide study from the Faroe Islands
Petersen, M. S., Hansen, C. B., Kristiansen, M. F., Fjallsbak, J. P., Larsen, S., Hansen, J. L., Jarlhelt, I., Perez Alos, L., a Steig, B., Christiansen, D. H., Moller, L. F., Strom, M., Andorsdottir, G., Gaini, S., Weihe, P., Garred, P.
10.1101/2021.04.19.21255720 — Posted: 2021-04-22 Discussion: Onsite
No evidence of significant cross-reactivity between the dengue virus (DENV) and SARS-CoV-2 IgG antibodies
Shurrab, F. M., Humaira, F., Al-Absi, E. S., Al-Sadeq, D. W., Qotba, H., Yassine, H. M., Abu-Raddad, L. J., Nasrallah, G. K.
10.1101/2021.04.19.21255725 — Posted: 2021-04-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).